Harvard’s George Church to join us at Endpoints 11 Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

M T W Thu F 14 August, 2025

PharmaForceIQ’s real-time customer engagement platform helps you reimagine what’s possible—driving agile campaigns with such strong ROI that 100% of clients renew. sponsored by PharmaForceIQ

spotlight The Endpoints 11: Join us Sept. 18 with George Church and this year's group of super-achievers

news Sarepta sells Arrowhead stake for cash and to help fulfill milestone payment Vedanta's microbiome therapy fails Phase 2, company lays off 20% CytomX discloses patient death in study of ADC in colorectal cancer

Principal - Life Science Alexandria Real Estate Equities San Francisco, CA, USA Senior Director of IT Caribou Biosciences, Inc. Berkeley, CA, USA Director Of Business Development, Health And Biomedical Innovation Brown University Providence, RI, USA Senior Patent Counsel Caribou Biosciences, Inc. Berkeley, CA, USA Head of Lab Operations Terray Therapeutics, Inc. Monrovia, CA, USA Principal Scientist, Molecular Design Terray Therapeutics, Inc. Monrovia, CA, USA Recruit talent with Endpoints Careers Contact Meg Estacio: mestacio@endpointsnews.com

Sep 04 11:00am ET Not just a tool: How AI agents become trial teammates sponsored by Medable Aug 21 2:00pm ET Agentic AI is here: Real-world applications in life sciences & healthcare sponsored by IBM

The biotech companies everyone will be talking about in 2025 get revealed live in Boston this September. Endpoints 11 isn’t just any list — it’s where industry insiders gather to see which bold bets might pay off. Find out who wins in real time at the State Room — reserve your spot now and save with the Early Bird rate.

endpoints pharma NIH backs away from mRNA research, claiming lack of public trust Pfizer says FDA may pull its Covid vaccine for young children US tariffs could undo generic drugmakers' efforts to be less reliant on Chinese raw materials, experts say

in case you missed it 1. The Endpoints Slack interview: AI bio backer Dylan Reid on techbio's original sin 2. Biotech industry goes six months without an IPO 3. VC firm Hatteras closes $200M for life sciences as it reaches 100th investment 4. Treg biotech Abata Therapeutics closes as money runs short